Výsledky vyhledávání - "Vanessa Esquibel"

A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC)

Autor: Neil J. Shah, Matthew T Campbell, Shifeng S. Mao, Moshe Chaim Ornstein, Naomi B. Haas, Xin Gao, Hans J. Hammers, Holavanahalli Keshava-Prasad, Hongxia Yan, Vanessa Esquibel, Robert B. Geller, Katy Beckermann

Publikováno v: Journal of Clinical Oncology. 41:666-666

666 Background: Activation of the GAS6/AXL pathway promotes tumor cell proliferation; high levels of GAS6 and AXL have been associated with drug resistance and decreased survival. Batiraxcept is an ultra-high affinity decoy protein that captures GAS6

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::474bcf67133e6c6629f2d300cc976ae9
https://doi.org/10.1200/jco.2023.41.6_suppl.666

Zobrazit plný text záznamu

A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib, cabozantinib and nivolumab, and as monotherapy in patients with advanced or metastatic clear cell renal cell carcinoma (NCT04300140)

Autor: Katy Beckermann, Neil J. Shah, Nicholas J. Vogelzang, Shifeng S. Mao, Moshe Chaim Ornstein, Hans J. Hammers, Xin Gao, David F. McDermott, Naomi B. Haas, Hongxia Yan, Vanessa Esquibel, Reshma A. Rangwala, Matthew T Campbell

Publikováno v: Journal of Clinical Oncology. 40:TPS4599-TPS4599

TPS4599 Background: In clear cell renal cell carcinoma (ccRCC) the constitutive expression of hypoxia induced factor 1-α leads to increased expression of AXL. AXL overexpression has been associated with the development of resistance to VEGF inhibito

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d29085ea13bca38cb074b77c9963e2ba
https://doi.org/10.1200/jco.2022.40.16_suppl.tps4599

Zobrazit plný text záznamu

A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib in patients with advanced or metastatic clear cell renal cell (ccRCC) carcinoma who have received front-line treatment (NCT04300140)

Autor: Neil J. Shah, Katy Beckermann, Nicholas J. Vogelzang, Shifeng S. Mao, Moshe Chaim Ornstein, Hans J. Hammers, Xin Gao, David F. McDermott, Naomi B. Haas, Hongxia Yan, Vanessa Esquibel, Reshma A. Rangwala, Matthew T Campbell

Publikováno v: Journal of Clinical Oncology. 40:4511-4511

4511 Background: AXL is up-regulated by hypoxia-inducible factor-1 signaling in both VHL-deficient and hypoxic tumor cells and plays a critical role in the metastatic phenotype of ccRCC. Batiraxcept is a recombinant fusion protein containing an extra

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f422c6a63934621eba1ffdcf57931ad5
https://doi.org/10.1200/jco.2022.40.16_suppl.4511

Zobrazit plný text záznamu

424 A phase 1b/2 randomized study of AVB-S6–500 in combination with cabozantinib versus cabozantinib alone in patients with advanced clear cell renal cell carcinoma who have received front-line treatment

Autor: Kathryn E. Beckermann, David F. McDermott, Hans J. Hammers, Xin Gao, Reshma A. Rangwala, Mao Shifeng, Matthew I. Campbell, Nicholas J. Vogelzang, Moshe Chaim Ornstein, Eduardo Pennella, Randy Anderson, Neil J. Shah, Eric Jonasch, Vanessa Esquibel

Publikováno v: Journal for ImmunoTherapy of Cancer. 9:A454-A454

BackgroundIn clear cell renal cell carcinoma (ccRCC) the constitutive expression of hypoxia induced factor 1-α leads to increased expression of AXL. AXL overexpression has been associated with the development of resistance to VEGF inhibitors and sup

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ccbd6f95af1501cdb9bb301175a3cb71
https://doi.org/10.1136/jitc-2021-sitc2021.424

Zobrazit plný text záznamu

TRTH-10. PEDIATRIC PHASE 1/1B STUDY OF ENTRECTINIB IN PATIENTS WITH PRIMARY BRAIN TUMORS, NEUROBLASTOMA, AND NTRK, ROS1, OR ALK FUSIONS

Autor: Sunitha Rangaraju, Pratik S. Multani, Edna Chow Maneval, Vanessa Esquibel, Zachary Hornby, Gang Li, Jason Christiansen

The STARTRK-NG (Studies of Tumor Alterations Responsive to Targeting Receptor Kinases - Next Generation) trial is a Phase 1/1b study of entrectinib in pediatric patients with cancer, including primary brain tumors, neuroblastoma, and other non-neurob

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eea32eac4ee358c77e2de00eca251a19
https://europepmc.org/articles/PMC5475194/

Zobrazit plný text záznamu

Placebo-Controlled Phase III Trial of Patient-Specific Immunotherapy With Mitumprotimut-T and Granulocyte-Macrophage Colony-Stimulating Factor After Rituximab in Patients With Follicular Lymphoma

Autor: Vanessa Esquibel, Sattva S. Neelapu, John F. Bender, Benjamin Djulbegovic, Craig R. Nichols, Michael J. Robertson, Jane N. Winter, Daniel P. Gold, Richard Ghalie, Paul A. Hamlin, Arnold S. Freedman, Morgan E. Stewart

Publikováno v: Journal of Clinical Oncology. 27:3036-3043

Purpose To evaluate patient-specific immunotherapy with mitumprotimut-T (idiotype keyhole limpet hemocyanin [Id-KLH]) and granulocyte-macrophage colony-stimulating factor (GM-CSF) in CD20+ follicular lymphoma. Patients and Methods Patients with treat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73d7023fcb82e38fe73110f264542f80
https://doi.org/10.1200/jco.2008.19.8903

Zobrazit plný text záznamu

Abstract B28: Overcoming drug resistance to Trk inhibition by rational combination of entrectinib and trametinib: from bench to bedside

Autor: Colin Walsh, Michael F. Berger, R. Patel, Pratik S. Multani, Zachary Hornby, Sofia Haque, Vanessa Esquibel, Gary Li, Ge Wei, Edna Chow Maneval

Publikováno v: Molecular Cancer Therapeutics. 16:B28-B28

Abnormal expression and constitutive activation of TrkA, TrkB and TrkC due to gene fusions are oncogenic drivers in many cancer types. Entrectinib, a potent, brain-penetrant Trk inhibitor, has demonstrated rapid, deep, and sustained clinical response

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b1384715a88fb74460be9c7352b2bd33
https://doi.org/10.1158/1538-8514.synthleth-b28

Zobrazit plný text záznamu

Abstract CT030: STARTRK-NG: A phase 1/1b study of entrectinib in children and adolescents with advanced solid tumors and primary CNS tumors, with or without TRK, ROS1, or ALK fusions

Autor: Amit J. Sabnis, Magaret Macy, Jennifer Foster, Cynthia Wetmore, Ami V. Desai, Suzanne Shusterman, Garrett M. Brodeur, Pratik S. Multani, Ellen M. Basu, Zachary Hornby, Vanessa Esquibel, Elizabeth Fox, Edna Chow Maneval

Publikováno v: Cancer Research. 77:CT030-CT030

Background: The STARTRK-NG (Studies of Tumor Alterations Responsive to Targeting Receptor Kinases - Next Generation) trial is a Phase 1/1b dose-escalation and expansion study of entrectinib in pediatric patients with cancer. Entrectinib is a potent o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::673d34ede42ca7a7e437eae016b9d99b
https://doi.org/10.1158/1538-7445.am2017-ct030

Zobrazit plný text záznamu

Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumors

Autor: Carla Kurkjian, Ofir Moreno, Wendy Levin, Manish R. Patel, Howard A. Burris, Shubham Pant, Johanna C. Bendell, Jeffrey R. Infante, Suzanne F. Jones, Kathleen N. Moore, Vanessa Esquibel

Publikováno v: Cancer

Background The current phase 1, open-label, dose escalation study was conducted to establish the safety, tolerability, pharmacokinetic profile, and preliminary antitumor activity of the novel mitochondrial inhibitor ME-344 in patients with refractory

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49d706c05d9ceb943426a1153f5f6799
https://pubmed.ncbi.nlm.nih.gov/25411085

Zobrazit plný text záznamu

Pracinostat in Combination with Azacitidine Produces a High Rate and Rapid Onset of Disease Remission in Patients with Previously Untreated Acute Myeloid Leukemia (AML)

Autor: Ehab Atallah, Olatoyosi Odenike, Steven Cha, Bruno C. Medeiros, Guillermo Garcia-Manero, Jorge E. Cortes, Vanessa Esquibel, Samer K. Khaled

Publikováno v: Blood. 124:947-947

Background: Pracinostat is a potent oral inhibitor of histone deacetylases (HDAC’s), selective for class I, II and IV isoforms. In-vitro cytotoxicity assays in AML cell lines revealed an IC50 of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cc4f72e6fb8840c173062f749168f620
https://doi.org/10.1182/blood.v124.21.947.947

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání